Literature DB >> 30616415

Increased risk of adverse acute myeloid leukemia after anti-CD19-targeted immunotherapies in KMT2A-rearranged acute lymphoblastic leukemia: a case report and review of the literature.

Elise Fournier1,2, Luca Inchiappa3, Carole Delattre1, Jean-Michel Pignon3, Frédérique Danicourt4, Maxime Bemba3, Catherine Roche-Lestienne5,6, Agnès Daudignon5, Gauthier Decool2,6, Christophe Roumier2,6, Florent Dumezy2,6, Loïc Fournier1, Nathalie Grardel2,6, Claude Preudhomme2,6, Nicolas Duployez2,6.   

Abstract

Entities:  

Year:  2019        PMID： 30616415     DOI： 10.1080/10428194.2018.1562185

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  3 in total

1.  Immunotherapy- (Blinatumomab-) Related Lineage Switch of KMT2A/AFF1 Rearranged B-Lymphoblastic Leukemia into Acute Myeloid Leukemia/Myeloid Sarcoma and Subsequently into B/Myeloid Mixed Phenotype Acute Leukemia.

Authors:  Rui R He; Zacharia Nayer; Matthew Hogan; Raymund S Cuevo; Kimberly Woodward; David Heyer; Christine A Curtis; Jess F Peterson
Journal:  Case Rep Hematol       Date:  2019-12-07

2.  LAMP-5 is an essential inflammatory-signaling regulator and novel immunotherapy target for mixed lineage leukemia-rearranged acute leukemia.

Authors:  Gabriel Gracia-Maldonado; Jason Clark; Matthew Burwinkel; Brenay Greenslade; Mark Wunderlich; Nathan Salomonis; Dario Leone; Evelina Gatti; Philippe Pierre; Ashish R Kumar; Lynn H Lee
Journal:  Haematologica       Date:  2022-04-01       Impact factor: 9.941

Review 3.  Does lineage plasticity enable escape from CAR-T cell therapy? Lessons from MLL-r leukemia.

Authors:  Wenjuan Liao; M Eric Kohler; Terry Fry; Patricia Ernst
Journal:  Exp Hematol       Date:  2021-07-21       Impact factor: 3.084
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.